CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited

1093.HK
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

1093.HK · Stock Price

HKD 8.26+2.52 (+43.90%)
Market Cap: $11.9B

Historical price data

Market Cap: $11.9BPipeline: 7 drugs (1 Phase 3)Founded: 1997Employees: 20,000-30,000HQ: Shijiazhuang, China

Overview

CSPC Pharmaceutical Group's mission is to deliver high-quality, accessible pharmaceutical products while advancing innovative therapeutics through sustained R&D investment. The company has achieved a dominant position in China's nervous system and cardiovascular markets, established itself as a global API supplier, and is now transitioning toward a more innovation-driven future with several novel drug candidates in late-stage development. Its strategy hinges on leveraging its integrated manufacturing and distribution strengths to maximize the lifecycle of its established products while systematically commercializing its innovative pipeline to capture higher-margin opportunities.

OncologyNervous SystemCardiovascular & MetabolicAnti-infectivesAutoimmune/Inflammatory

Technology Platform

Integrated platform spanning small molecule discovery, biologics/antibody-drug conjugate (ADC) development, advanced drug delivery systems, and scalable process manufacturing.

Pipeline

7
7 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
Butylphthalide + Butylphthalide placeboST-segment Elevation Myocardial Infarction (STEMI)Phase 3
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen...Leukemia, Myeloid, AcutePhase 2
pegylated liposomal doxorubicin (PLD) + PD-1Muscle Invasive Bladder CancerPhase 2
Sintilimab + Nab paclitaxel + CisplatinEsophageal Squamous Cell CarcinomaPhase 2
Mitoxantrone hydrochloride liposome Injection-based bridging...B-cell Acute Lymphoblastic LeukemiaPhase 2

FDA Approved Drugs

1
CONJUPRINDADec 19, 2019